S. Calabro

发表

Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

A. Gottlieb, L. Naldi, K. Papp, 2015, Journal of drugs in dermatology : JDD.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).

B. Strober, M. Lebwohl, L. Naldi, 2016, Journal of the American Academy of Dermatology.

PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.

B. Strober, K. Papp, M. Augustin, 2012, Journal of drugs in dermatology : JDD.

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.

A. Gottlieb, L. Ferris, F. Kerdel, 2012, Journal of the American Academy of Dermatology.

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

M. Lebwohl, Y. You, C. Leonardi, 2015, JAMA dermatology.

Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

A. Menter, M. Gooderham, K. Papp, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)*

A. Menter, W. Gulliver, C. Leonardi, 2014, The British journal of dermatology.

Mo1884 Prevalence of Inflammatory Bowel Disease Among Patients With Psoriasis and Incidence of Serious Infections in This Subset: Results From the PSOLAR Registry

M. Augustin, E. Loftus, G. Krueger, 2016 .

Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.

A. Gottlieb, A. Menter, E. D. De Jong, 2014, Journal of drugs in dermatology : JDD.

WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).

A. Gottlieb, L. Naldi, K. Papp, 2015, Journal of the American Academy of Dermatology.

Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.

A. Gottlieb, A. Blauvelt, D. Amato, 2013, Journal of drugs in dermatology : JDD.

Correlation of psoriasis activity with socioeconomic status: cross‐sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

A. Kimball, K. Gordon, M. Augustin, 2018, The British journal of dermatology.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])

B. Strober, M. Lebwohl, L. Naldi, 2016 .

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)

A. Kimball, A. Menter, C. Leonardi, 2014, The British journal of dermatology.